The tweet was deleted by the author.
But we saved everything 🙂.
Cullinan Therapeutics participated in the ITP Conference 2026 organized by @PDSA_ITP, aiming to engage with patients and physicians involved in immune thrombocytopenia (ITP).
The event offered an opportunity for the company to connect, learn, and strengthen its relationships within the ITP community. Cullinan Therapeutics continues to actively collaborate with stakeholders in the rare hematology field. Details about specific outcomes or initiatives discussed at the conference were not disclosed.
View post on X Loading...
Cullinan Therapeutics recently posted its Q2 2026 financial results and provided updates on milestones for its T cell engager pipeline here. The company is also advancing CLN-978, a CD19-directed T cell engager targeting major autoimmune diseases such as rheumatoid arthritis here. These initiatives reflect Cullinan's ongoing commitment to developing therapies in hematology and immune disorders.